LAB - Standard BioTools Inc.
Chart Events
Williams %R
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 2.2800 |
| Open | 2.2800 |
| Bid | 2.2400 x 800 |
| Ask | 2.2500 x 900 |
| Day's Range | 2.2200 - 2.3000 |
| 52 Week Range | 0.9200 - 2.6500 |
| Volume | |
| Avg. Volume | 307,896 |
| Market Cap | 174.798M |
| Beta (5Y Monthly) | 1.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6900 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.70 |
Fair Value
Related Research
GlobeNewswireStandard BioTools to Present at the Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will give a presentation at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 9:00 a.m. ET. The presentation will be webcast live and available on the Investor Relations page of the company’s website at Events & Pre
Simply Wall St.With Standard BioTools Up 29%, Insider Buyers Count Their Returns \
Standard BioTools Inc. ( NASDAQ:LAB ) insiders who purchased shares in the last 12 months were richly rewarded last...
- Simply Wall St.
Jeffrey Black Spends US$194k On Standard BioTools Stock \
Investors who take an interest in Standard BioTools Inc. ( NASDAQ:LAB ) should definitely note that the Senior VP...
- GlobeNewswire
Standard BioTools Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System
Supporting discovery through screening, the X9 is the only system integrating real-time PCR and NGS library preparationSOUTH SAN FRANCISCO, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the launch of NGS library preparation functionality on the X9™ High-Throughput Genomics System. For the first time ever, customers can perform real-time PCR and next-generation
- GlobeNewswire
Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Industry veteran Jeffrey Black brings 30 years of financial and operating leadership experience Vikram Jog to become Special Advisor for transition period SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced the appointment of Jeffrey Black as Senior Vice President and Chief Financial Officer effective today. Black will lead Standard BioTools’ finance
Insider MonkeyStandard BioTools Inc. (NASDAQ:LAB) Q1 2023 Earnings Call Transcript
Standard BioTools Inc. (NASDAQ:LAB) Q1 2023 Earnings Call Transcript May 9, 2023 Operator: Hello, and welcome to the Standard BioTools Incoporated First Quarter 2023 Financial Results Conference Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Peter DeNardo, Investor Relations. Thank you. Mr. DeNardo, you may […]
- Thomson Reuters StreetEvents
Q1 2023 Standard BioTools Inc Earnings Call
Q1 2023 Standard BioTools Inc Earnings Call
- GlobeNewswire
Standard BioTools Reports First Quarter 2023 Financial Results
Net cash used in operating activities of $8.5 million, a 55.8% sequential decline from $19.2 million in the fourth quarter and a 46% reduction from the $15.6 in the first quarter last year GAAP revenue (includes discontinued/COVID-19 products) decreased 5.2% year-over-year to $25.1 million, with a 1.8% year-over-year increase in ongoing, core product and service revenue to $24.3 million GAAP product and services margin of 46.6%, an improvement of 567 basis points over fourth quarter 2022; non-GA
- GlobeNewswire
Standard BioTools Announces Conference Call and Webcast for First Quarter 2023 Financial Results
SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of the market. The Company’s management will host a conference call and webcast at 2:00 p.m. PT, 5:00 p.m. ET, on May 9, 2023, to discuss first quarter 2023 financial results and operational prog
- GlobeNewswire
Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards, effective as of April 20, 2023, under the Standard BioTools Inc. 2022 Inducement Equity Incentive Plan (Inducement Plan), as a material inducement to four individuals entering into employment with Standard BioTools. The equity awards were approved i
- Simply Wall St.
Standard BioTools Inc.'s (NASDAQ:LAB) Low P/S No Reason For Excitement
Standard BioTools Inc.'s ( NASDAQ:LAB ) price-to-sales (or "P/S") ratio of 1.5x might make it look like a strong buy...
- GlobeNewswire
Standard BioTools introduces the Hyperion XTi Imaging System, breaks barriers to power significant advancement in spatial biology
New tissue imaging tool designed to revolutionize clinical researchSOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the launch of its newest imaging technology, the Hyperion XTi™ Imaging System, during the American Association for Cancer Research (AACR) meeting in Orlando. The new system is expected to cement the company’s position in the e
- GlobeNewswire
Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of March 20, 2023, under the Standard BioTools Inc. 2022 Inducement Equity Incentive Plan (Plan). The equity award consisted of an award of nonstatutory stock options to purchase 647,112 shares of common stock and an award of 112,293 r
- GlobeNewswire
Standard BioTools Announces Appointment of Fenel Eloi to Board of Directors
Experienced Life Science Operating Leader Joins Board as Company Enters New PhaseSOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the appointment of Fenel Eloi to its Board of Directors (“Board”). Eloi will also serve on the Board’s Audit Committee. Eloi was most recently the Chief Financial Officer and then Chief Operating Officer of Cell
- GlobeNewswire
Standard BioTools to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, at 3:00 p.m. ET. The presentation will be webcast live and available on the Investor Relations
- GlobeNewswire
Standard BioTools to Present at 43rd Annual Cowen Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will present at the Cowen Health Care Conference on Wednesday, March 8, 2023, at 12:50 p.m. ET. The presentation will be webcast live and available on the Investor Relations page of the company’s website at Events & Presentations
Insider MonkeyStandard BioTools Inc. (NASDAQ:LAB) Q4 2022 Earnings Call Transcript
Standard BioTools Inc. (NASDAQ:LAB) Q4 2022 Earnings Call Transcript February 14, 2023 Operator: Hello, and welcome to the Standard BioTools Inc. Fourth Quarter and Full Year 2022 Financial Results Conference Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Peter DeNardo, Investor Relations. Thank you. Mr. […]
American City Business JournalsHow a Peninsula biotech tools company looks to corral 'one-trick ponies'
The 24-year-old company, founded as Fluidigm, got a $250 million influx from two hedge funds and brought in new management.
- GlobeNewswire
Standard BioTools Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Business Outlook
Fourth quarter 2022 GAAP revenues of $27.0 million; Core product and service revenues of $26.8 million, representing 8.3% sequential growth; Full year GAAP revenues of $97.9 million and core product and service revenues of $94.5 million Improved operating discipline and restructuring initiatives contributed to a 16% sequential decrease in operating expenses in the fourth quarter; Product and services margin improved sequentially by 620 basis points on a GAAP basis, 520 basis points on a non-GAAP
- Simply Wall St.
The past five years for Standard BioTools (NASDAQ:LAB) investors has not been profitable
Standard BioTools Inc. ( NASDAQ:LAB ) shareholders will doubtless be very grateful to see the share price up 82% in the...
- GlobeNewswire
Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report fourth quarter and full year 2022 financial results on Tuesday, February 14, 2023, after the close of the market. The Company’s management will host a conference call and webcast at 2:00 p.m. PT, 5:00 p.m. ET, on February 14, 2023, to discuss fourth quarter and full year 20
- GlobeNewswire
Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update
Continued commercial and strategic execution delivers sequential core revenue growth of 4%–9% to $26 million–$27 million in Q4 2022 for full year total of approximately $94 million–$95 million Business restructuring and SBS program on track to deliver over 20% reduction in operating expenses or more than $30 million and reduces annual operating expenses to approximately $100 million exiting Q4. GAAP operating expense reductions are expected to be over 25% and over $35 million. On track for achie
- GlobeNewswire
Standard BioTools Announces Appointment of Betsy Jensen as Chief Human Resources Officer
Former Danaher Executive Further Strengthens Senior Management TeamSOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the appointment of Betsy Jensen as Chief Human Resources Officer. Jensen will lead Standard BioTools™ human resources function and will report to President and Chief Executive Officer Michael Egholm, PhD. An essential element o
- Simply Wall St.
Standard BioTools Inc. (NASDAQ:LAB) institutional owners may be pleased with recent gains after 64% loss over the past year
If you want to know who really controls Standard BioTools Inc. ( NASDAQ:LAB ), then you'll have to look at the makeup...
- GlobeNewswire
Standard BioTools Authorizes up to $20 Million of Share Repurchases
SOUTH SAN FRANCISCO, Calif., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that its board of directors has authorized the repurchase of up to $20 million of shares of its common stock in the open market or in negotiated transactions through December 31, 2023. The repurchases are expected to be made from cash on hand, which the Company’s board believes is an effective